Loading clinical trials...
Loading clinical trials...
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
Conditions
Interventions
IFN-alpha2a
Locations
1
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
April 7, 2005
Primary Completion Date
May 26, 2023
Completion Date
May 26, 2023
Last Updated
December 11, 2024
NCT07445984
NCT01137825
NCT01366612
NCT02158858
NCT05969821
NCT01684150
Lead Sponsor
M.D. Anderson Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions